多中心研究伊曲康唑 MIC 分布和曲霉属的 CLSI M38-A2 肉汤微量稀释法的流行病学截断值。
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.
机构信息
VCU Medical Center, Richmond, Virginia, USA.
出版信息
Antimicrob Agents Chemother. 2013 Aug;57(8):3823-8. doi: 10.1128/AAC.00636-13. Epub 2013 May 28.
Abstract
Epidemiological cutoff values (ECVs) were established for the new triazole isavuconazole and Aspergillus species wild-type (WT) MIC distributions (organisms in a species-drug combination with no detectable acquired resistance mechanisms) that were defined with 855 Aspergillus fumigatus, 444 A. flavus, 106 A. nidulans, 207 A. niger, 384 A. terreus, and 75 A. versicolor species complex isolates; 22 Aspergillus section Usti isolates were also included. CLSI broth microdilution MIC data gathered in Europe, India, Mexico, and the United States were aggregated to statistically define ECVs. ECVs were 1 μg/ml for the A. fumigatus species complex, 1 μg/ml for the A. flavus species complex, 0.25 μg/ml for the A. nidulans species complex, 4 μg/ml for the A. niger species complex, 1 μg/ml for the A. terreus species complex, and 1 μg/ml for the A. versicolor species complex; due to the small number of isolates, an ECV was not proposed for Aspergillus section Usti. These ECVs may aid in detecting non-WT isolates with reduced susceptibility to isavuconazole due to cyp51A (an A. fumigatus species complex resistance mechanism among the triazoles) or other mutations.
摘要
建立了新的三唑类药物伊曲康唑和曲霉属野生型（WT）MIC 分布的流行病学截断值（ECVs），这些分布是通过 855 株烟曲霉、444 株黄曲霉、106 株构巢曲霉、207 株黑曲霉、384 株土曲霉和 75 株彩绒革盖菌复合种的分离株以及 22 株曲霉属 Usti 分离株来定义的。汇总了来自欧洲、印度、墨西哥和美国的 CLSI 肉汤微量稀释 MIC 数据，以统计方式定义 ECVs。烟曲霉复合种的 ECV 为 1μg/ml，黄曲霉复合种的 ECV 为 1μg/ml，构巢曲霉复合种的 ECV 为 0.25μg/ml，黑曲霉复合种的 ECV 为 4μg/ml，土曲霉复合种的 ECV 为 1μg/ml，彩绒革盖菌复合种的 ECV 为 1μg/ml；由于分离株数量较少，因此未提出 Aspergillus section Usti 的 ECV。这些 ECVs 可能有助于检测由于 cyp51A（三唑类药物中烟曲霉复合种的一种耐药机制）或其他突变而导致对伊曲康唑敏感性降低的非 WT 分离株。
相似文献
1
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.多中心研究伊曲康唑 MIC 分布和曲霉属的 CLSI M38-A2 肉汤微量稀释法的流行病学截断值。
Antimicrob Agents Chemother. 2013 Aug;57(8):3823-8. doi: 10.1128/AAC.00636-13. Epub 2013 May 28.
2
Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).CLSI 肉汤微量稀释法（M38-A2 文件）中三唑类药物和六种曲霉菌属的野生型 MIC 分布和流行病学折点值。
J Clin Microbiol. 2010 Sep;48(9):3251-7. doi: 10.1128/JCM.00536-10. Epub 2010 Jun 30.
3
Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates.评估伊曲康唑和比较剂伏立康唑对 2635 株当代临床念珠菌和曲霉菌分离株的体外活性。
Clin Microbiol Infect. 2017 Nov;23(11):882-887. doi: 10.1016/j.cmi.2017.03.023. Epub 2017 Apr 1.
4
Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).CLSI 肉汤微量稀释法（M38-A2 文件）中用于检测棘白菌素和曲霉菌属的野生型 MIC 分布和流行病学折点值。
Antimicrob Agents Chemother. 2011 Jun;55(6):2855-9. doi: 10.1128/AAC.01730-10. Epub 2011 Mar 21.
5
Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles.利用流行病学截断值研究 9 年来 Aspergillus 属对三唑类药物敏感性的变化趋势。
J Clin Microbiol. 2011 Feb;49(2):586-90. doi: 10.1128/JCM.02136-10. Epub 2010 Dec 1.
6
Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).CLSI 肉汤微量稀释法（M38-A2 文件）中两性霉素 B 和曲霉菌属的野生型 MIC 分布和流行病学折点值。
Antimicrob Agents Chemother. 2011 Nov;55(11):5150-4. doi: 10.1128/AAC.00686-11. Epub 2011 Aug 29.
7
In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole.烟曲霉对伊曲康唑、伏立康唑和泊沙康唑的体外药敏性：与伏立康唑的相关性。
Antimicrob Agents Chemother. 2013 Nov;57(11):5778-80. doi: 10.1128/AAC.01141-13. Epub 2013 Sep 16.
8
Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.比较 Sensititre YeastOne 和 CLSI M38-A2 微量稀释法测定两性霉素 B、伊曲康唑、伏立康唑和泊沙康唑对曲霉属的活性。
J Clin Microbiol. 2018 Sep 25;56(10). doi: 10.1128/JCM.00780-18. Print 2018 Oct.
9
In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.新型抗真菌化合物 F901318 对难治疗的曲霉属分离株的体外活性。
J Antimicrob Chemother. 2017 Sep 1;72(9):2548-2552. doi: 10.1093/jac/dkx177.
10
Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories.伊曲康唑对两个真菌学参考实验室的机会性真菌病原体的活性。
Antimicrob Agents Chemother. 2018 Sep 24;62(10). doi: 10.1128/AAC.01230-18. Print 2018 Oct.
引用本文的文献
1
Exploring Factors Driving the Uneven Distribution of in an Austrian Hotspot Region.探索奥地利一个热点地区[具体内容缺失]分布不均的驱动因素。
Microorganisms. 2025 May 27;13(6):1218. doi: 10.3390/microorganisms13061218.
2
Evaluation of the Activity of Triazoles Against Non- and Cryptic Species Causing Invasive Infections Tested in the SENTRY Program.在哨兵计划中对三唑类药物针对引起侵袭性感染的非典型和隐匿性物种的活性进行评估。
Open Forum Infect Dis. 2024 Nov 1;11(11):ofae532. doi: 10.1093/ofid/ofae532. eCollection 2024 Nov.
3
Synergistic action of lactoferrin and its derived functional fragments as a promising therapeutic agent in combating mucormycosis.乳铁蛋白及其衍生功能片段的协同作用作为一种有前途的抗毛霉病治疗药物。
Future Microbiol. 2024 Jul 2;19(10):857-866. doi: 10.1080/17460913.2024.2352263. Epub 2024 Jun 21.
4
Trends in the activity of mold-active azole agents against clinical isolates with and without alterations from Europe and North America (2017-2021).欧洲和北美地区（2017-2021 年）具有和不具有改变的临床分离株中，对霉菌活性唑类药物的活性趋势。
J Clin Microbiol. 2024 Feb 14;62(2):e0114123. doi: 10.1128/jcm.01141-23. Epub 2024 Jan 9.
5
In Vitro Activity of Isavuconazole and Other Mould-Active Azoles against with and without CYP51 Alterations.艾沙康唑及其他对霉菌有活性的唑类药物在有和无CYP51改变情况下的体外活性
J Fungi (Basel). 2023 May 25;9(6):608. doi: 10.3390/jof9060608.
6
Species Distribution and Antifungal Susceptibilities of Section Isolates in Clinical Samples from the United States and Description of sp. nov.美国临床样本中某属菌株的物种分布及抗真菌药敏情况与新种描述
Pathogens. 2023 Apr 11;12(4):579. doi: 10.3390/pathogens12040579.
7
Diagnosis and Treatment of Invasive Aspergillosis Caused by Non- spp.非烟曲霉属引起的侵袭性曲霉病的诊断与治疗
J Fungi (Basel). 2023 Apr 21;9(4):500. doi: 10.3390/jof9040500.
8
Multicenter Study of Susceptibility of Aspergillus Species Isolated from Iranian University Hospitals to Seven Antifungal Agents.伊朗大学医院分离的曲霉菌属对七种抗真菌药物的敏感性的多中心研究。
Microbiol Spectr. 2022 Jun 29;10(3):e0253921. doi: 10.1128/spectrum.02539-21. Epub 2022 May 17.
9
Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections.COVID-19 对监测侵袭性真菌感染的全球监测计划中收集的分离株的抗真菌药敏谱的影响。
Med Mycol. 2022 May 6;60(5). doi: 10.1093/mmy/myac028.
10
Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011-2019).亚洲和西太平洋地区机会性丝状真菌病原体的抗真菌药敏性：来自 SENTRY 抗真菌监测计划（2011-2019 年）的数据。
J Antibiot (Tokyo). 2021 Aug;74(8):519-527. doi: 10.1038/s41429-021-00431-4. Epub 2021 Jun 30.
本文引用的文献
1
In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration.体内出现对唑类药物敏感性降低且 Cyp51a M217I 改变的土曲霉。
J Infect Dis. 2012 Sep 15;206(6):981-5. doi: 10.1093/infdis/jis442. Epub 2012 Jul 10.
2
Epidemiological cutoff values for azoles and Aspergillus fumigatus based on a novel mathematical approach incorporating cyp51A sequence analysis.基于包含 Cyp51A 序列分析的新型数学方法的抗真菌药物和烟曲霉的流行病学截止值。
Antimicrob Agents Chemother. 2012 May;56(5):2524-9. doi: 10.1128/AAC.05959-11. Epub 2012 Feb 13.
3
Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India.在印度从携带 cyp51A 基因 TR/L98H 突变的多唑耐药烟曲霉分离株。
J Antimicrob Chemother. 2012 Feb;67(2):362-6. doi: 10.1093/jac/dkr443. Epub 2011 Oct 25.
4
Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature.唑类药物治疗期间烟曲霉中多种耐药机制的快速诱导：病例研究及文献复习。
Antimicrob Agents Chemother. 2012 Jan;56(1):10-6. doi: 10.1128/AAC.05088-11. Epub 2011 Oct 17.
5
Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009.2007-2009 年荷兰烟曲霉唑类耐药的临床意义。
Emerg Infect Dis. 2011 Oct;17(10):1846-54. doi: 10.3201/eid1710.110226.
6
In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.体外异帕米星对 208 株黄曲霉与其他 7 种抗真菌药物的活性比较：根据欧洲抗菌药物敏感性测试委员会方法学进行评估。
Diagn Microbiol Infect Dis. 2011 Dec;71(4):370-7. doi: 10.1016/j.diagmicrobio.2011.08.006. Epub 2011 Sep 19.
7
Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).CLSI 肉汤微量稀释法（M38-A2 文件）中两性霉素 B 和曲霉菌属的野生型 MIC 分布和流行病学折点值。
Antimicrob Agents Chemother. 2011 Nov;55(11):5150-4. doi: 10.1128/AAC.00686-11. Epub 2011 Aug 29.
8
Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).CLSI 肉汤微量稀释法（M38-A2 文件）中用于检测棘白菌素和曲霉菌属的野生型 MIC 分布和流行病学折点值。
Antimicrob Agents Chemother. 2011 Jun;55(6):2855-9. doi: 10.1128/AAC.01730-10. Epub 2011 Mar 21.
9
Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).CLSI 肉汤微量稀释法（M38-A2 文件）中三唑类药物和六种曲霉菌属的野生型 MIC 分布和流行病学折点值。
J Clin Microbiol. 2010 Sep;48(9):3251-7. doi: 10.1128/JCM.00536-10. Epub 2010 Jun 30.
10
Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.伊曲康唑：一种新型三唑类药物的活性谱的全面综述。
Mycopathologia. 2010 Nov;170(5):291-313. doi: 10.1007/s11046-010-9324-3. Epub 2010 Jun 5.
Zotero 插件